Subgroup univariable analysis of outcomes in patients treated with auto-HCT or CAR-T while in a PR in patients with known positive PET scan before treatment
. | Auto-HCT (N = 222) . | CAR-T (N = 126) . | . | ||
---|---|---|---|---|---|
Outcomes . | N eval . | Prob (95% CI) . | N eval . | Prob (95% CI) . | P value . |
Nonrelapse mortality | 215 | 119 | .2* | ||
100 d | 3% (1-5) | 2% (0-5) | .5† | ||
1 y | 6% (3-9) | 3% (1-6) | .1† | ||
2 y | 7% (4-11) | 3% (1-6) | .04† | ||
Progression/relapse | 215 | 119 | .007* | ||
1 y | 33% (27-39) | 46% (36-55) | .03† | ||
2 y | 39% (32-46) | 54% (42-66) | .03† | ||
Progression-free survival | 215 | 119 | .04* | ||
1 y | 61% (55-68) | 52% (42-61) | .1† | ||
2 y | 54% (47-61) | 43% (32-55) | .1† | ||
Overall survival | 222 | 126 | .005* | ||
1 y | 79% (73-84) | 69% (60-77) | .06† | ||
2 y | 71% (65-77) | 49% (34-63) | .006† |
. | Auto-HCT (N = 222) . | CAR-T (N = 126) . | . | ||
---|---|---|---|---|---|
Outcomes . | N eval . | Prob (95% CI) . | N eval . | Prob (95% CI) . | P value . |
Nonrelapse mortality | 215 | 119 | .2* | ||
100 d | 3% (1-5) | 2% (0-5) | .5† | ||
1 y | 6% (3-9) | 3% (1-6) | .1† | ||
2 y | 7% (4-11) | 3% (1-6) | .04† | ||
Progression/relapse | 215 | 119 | .007* | ||
1 y | 33% (27-39) | 46% (36-55) | .03† | ||
2 y | 39% (32-46) | 54% (42-66) | .03† | ||
Progression-free survival | 215 | 119 | .04* | ||
1 y | 61% (55-68) | 52% (42-61) | .1† | ||
2 y | 54% (47-61) | 43% (32-55) | .1† | ||
Overall survival | 222 | 126 | .005* | ||
1 y | 79% (73-84) | 69% (60-77) | .06† | ||
2 y | 71% (65-77) | 49% (34-63) | .006† |